Verona Pharmaceuticals reported positive results from a phase 2 trial evaluating a pressurized metered-dose inhaler (“pMDI”) formulation of ensifentrine in patients with moderate to severe…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.